Bladder Cancer News and Research RSS Feed - Bladder Cancer News and Research

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year. In addition, the cancers of many previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70% bladder cancer patients have the non-muscle-invasive form of bladder cancer at diagnosis.
Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

In the first study of its kind, Penn researchers have shown how an anti-diabetic drug can have variable effects depending on small natural differences in DNA sequence between individuals. Mitchell Lazar, MD, PhD, Raymond Soccio, MD, PhD, and colleagues at the Perelman School of Medicine at the University of Pennsylvania, aim to apply this knowledge to develop personalized approaches to treating diabetes and other metabolic disorders. [More]
BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories. [More]
Telesta submits Biologics License Application for MCNA to FDA

Telesta submits Biologics License Application for MCNA to FDA

Telesta Therapeutics Inc. announced today that it has submitted electronically, through its U.S. agent, a Biologics License Application (BLA) to the United States Food and Drug Administration for MCNA. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy. [More]
E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder cancer

E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder cancer

Investigators from Dartmouth's Norris Cotton Cancer Center harnessed genomic data to discover that the previously identified E2F4 signature in breast cancer can be utilized to predict prognosis and response to therapy in bladder cancer. [More]
The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Minimally Invasive Urology Institute at The Miriam Hospital is offering UroLift as one of the newest surgical treatments available for men with benign prostatic hyperplasia (BPH), an enlarged prostate condition. [More]
Nanoplatform technology that detects early stages of cancer receives U.S. patent

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear. [More]
Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone. [More]
New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Foundation Medicine, Inc. today presented new data including promising clinical outcomes underscoring the importance of integrating comprehensive genomic profiling with FoundationOneĀ® into clinical oncology care for the treatment of biliary tract cancers. [More]
Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC). [More]
BioLight Life Sciences reports operational and financial results for Q1 2015

BioLight Life Sciences reports operational and financial results for Q1 2015

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the first quarter ended March 31, 2015. [More]
Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer (CRC) with high microsatellite instability (MSI-H), a predisposition that occurs in 15% of all CRCs causing significantly different prognosis and response to treatment. [More]
Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015. [More]
OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis. [More]

Rocheā€™s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Data to be presented at the 51st Annual Meeting of the American Society of Clinical Oncology suggest that the investigational immunotherapy MPDL3280A may double the likelihood of overall survival in the study period (HR=0.47), compared with docetaxel chemotherapy, in individuals with non-small cell lung cancer (NSCLC) who expressed the highest levels of PD-L1 (a receptor present on cancer cells). [More]

Study shows superiority of Cxbladder Detect over other non-invasive bladder cancer diagnostic tool

Newly published research demonstrates that Cxbladder out performs other non-invasive bladder cancer diagnostics, announced Pacific Edge, Ltd. The new research comparing and ranking four widely used tests was published online this week in the peer-reviewed Open Access medical journal BioMed Central ("BMC") Medical Research Methodology. [More]
GHIT Fund expands investments in leishmaniasis, diagnostic tests

GHIT Fund expands investments in leishmaniasis, diagnostic tests

The Global Health Innovative Technology Fund, which in the last two years has funded almost $32 million for innovative tools to tackle global infectious diseases, today announced additional investments of nearly $11 million that bring its portfolio to approximately $43 million. [More]
Post-operative atrial fibrillation can significantly increase risk of heart attack or stroke

Post-operative atrial fibrillation can significantly increase risk of heart attack or stroke

As many as 12 percent of patients undergoing major, non-cardiac surgery experience an irregular heartbeat called atrial fibrillation. [More]
Study highlights link between poor sleep quality and impact of severe LUTS in some men

Study highlights link between poor sleep quality and impact of severe LUTS in some men

Sleep quality may have an impact on the severity of lower urinary tract symptoms, or LUTS, in some men, according to new research presented during the 110th Annual Scientific Meeting of the American Urological Association. [More]
Quitting smoking can help improve outcomes after major urologic surgery

Quitting smoking can help improve outcomes after major urologic surgery

Quitting smoking can lead to a significant improvement in outcomes after major urologic surgery. These new data and their impact on urologic surgery will be highlighted by study authors during a special press conference at the 110th Annual Scientific Meeting of the American Urological Association. [More]
Dan Theodorescu awarded Barringer Medal for distinguished contributions to urology

Dan Theodorescu awarded Barringer Medal for distinguished contributions to urology

Dan Theodorescu, MD, PhD, director of the NCI-designated University of Colorado Cancer Center and professor of Urology and Pharmacology at the University of Colorado School of Medicine was awarded the Barringer Medal this past Saturday from the American Association of Genitourinary Surgeons for his distinguished contributions to urology. [More]
Advertisement
Advertisement